[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kura Oncology (KURA)

Kura Oncology (KURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 816,721
  • Shares Outstanding, K 88,774
  • Annual Sales, $ 67,480 K
  • Annual Income, $ -278,670 K
  • EBIT $ -318 M
  • EBITDA $ -325 M
  • 60-Month Beta 0.32
  • Price/Sales 12.13
  • Price/Cash Flow N/A
  • Price/Book 7.59

Options Overview Details

View History
  • Implied Volatility 46.05% (-20.60%)
  • Historical Volatility 43.25%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 434.09% on 02/04/26
  • IV Low 46.05% on 05/19/26
  • Expected Move (DTE 30) 1.33 (14.59%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 1,345
  • Volume Avg (30-Day) 327
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 4,402
  • Open Int (30-Day) 6,207
  • Expected Range 7.76 to 10.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.90
  • Number of Estimates 5
  • High Estimate $-0.84
  • Low Estimate $-1.01
  • Prior Year $-0.75
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.53 +5.16%
on 04/29/26
10.03 -10.61%
on 04/21/26
-0.71 (-7.33%)
since 04/17/26
3-Month
7.53 +19.04%
on 03/30/26
10.03 -10.61%
on 04/21/26
+0.39 (+4.55%)
since 02/19/26
52-Week
5.45 +64.59%
on 08/11/25
12.49 -28.18%
on 11/14/25
+2.73 (+43.75%)
since 05/19/25

Most Recent Stories

More News
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7 th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura...

KURA : 8.96 (-2.61%)
Kura Oncology Q1 Earnings Call Highlights

Kura Oncology (NASDAQ:KURA) reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad...

KURA : 8.96 (-2.61%)
Kura Oncology: Q1 Earnings Snapshot

Kura Oncology: Q1 Earnings Snapshot

KURA : 8.96 (-2.61%)
Kura Oncology Reports First Quarter 2026 Financial Results

– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching...

KURA : 8.96 (-2.61%)
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both...

KURA : 8.96 (-2.61%)
Kura Oncology's Commercial Transition May Finally Show Up in the Revenue Line

Barchart Research What to Expect from KURA Earnings KURA Generated May 11, 2026 Current Price $9.51 EPS Estimate $$-0.88 Consensus Rating Strong Buy Average Move 1.98% Kura Oncology's Commercial Transition...

KURA : 8.96 (-2.61%)
Kura Oncology's Commercial Launch Trajectory Will Either Validate or Undermine Its Valuation

Barchart Research What to Expect from KURA Earnings KURA Generated May 6, 2026 Current Price $9.56 EPS Estimate $$-0.88 Consensus Rating Strong Buy Average Move 1.98% Kura Oncology's Commercial Launch...

KURA : 8.96 (-2.61%)
Kura Oncology to Participate in Bank of America Securities Healthcare Conference

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 8.96 (-2.61%)
Kura Oncology to Report First Quarter 2026 Financial Results

SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 8.96 (-2.61%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 8.96 (-2.61%)

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

3rd Resistance Point 9.93
2nd Resistance Point 9.72
1st Resistance Point 9.46
Last Price 8.96
1st Support Level 8.99
2nd Support Level 8.78
3rd Support Level 8.52

See More

52-Week High 12.49
Fibonacci 61.8% 9.80
Fibonacci 50% 8.97
Last Price 8.96
Fibonacci 38.2% 8.14
52-Week Low 5.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.